5558-95-2 Usage
General Description
2-(Trichloromethyl)quinazolin-4(3H)-one is a chemical compound with the molecular formula C9H5Cl3N2O. It is a quinazolinone derivative with a trichloromethyl group attached to the quinazolinone ring. 2-(TRICHLOROMETHYL)QUINAZOLIN-4(3H)-ONE is a potential intermediate in the synthesis of various pharmaceuticals and agrochemicals. It has been studied for its potential biological and pharmacological activities, including its antiviral and antimicrobial properties. The trichloromethyl group in the compound also makes it useful as a reagent in organic synthesis for the introduction of the trichloromethyl moiety in other molecules. Overall, 2-(trichloromethyl)quinazolin-4(3H)-one is a versatile compound with potential applications in various fields, including medicine and agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 5558-95-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,5,5 and 8 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5558-95:
(6*5)+(5*5)+(4*5)+(3*8)+(2*9)+(1*5)=122
122 % 10 = 2
So 5558-95-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H5Cl3N2O/c10-9(11,12)8-13-6-4-2-1-3-5(6)7(15)14-8/h1-4H,(H,13,14,15)
5558-95-2Relevant articles and documents
Sonogashira cross-coupling reaction in 4-chloro-2- trichloromethylquinazoline series is possible despite a side dimerization reaction
Kieffer, Charline,Verhaeghe, Pierre,Primas, Nicolas,Castera-Ducros, Caroline,Gellis, Armand,Rosas, Roselyne,Rault, Sylvain,Rathelot, Pascal,Vanelle, Patrice
, p. 2987 - 2995 (2013/03/29)
We studied the Sonogashira coupling reaction between 4-chloro-2- trichloromethylquinazoline and various terminal alkynes, mainly in phenylacetylene series. A brief review of the literature shows that mono- or polybromo/chloromethylated substrates, especia
QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY
-
Page/Page column 16-17, (2008/12/08)
The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.
